TAT 2017
Wednesday, March 8, 2017

08:30 - 10:10Plenary Session 9: Targeting cancer metabolism [More Info]
Chair: Susan Bates, Columbia University, New York, NY, USA
Chair: Antoine Italiano, Institut BergoniƩ, Bordeaux, France
08:30 - 08:50O9.1 Cancer cell metabolism and its vulnerabilities [More Info]
Guido Kroemer, University Paris Descartes, Paris, France
08:50 - 09:10O9.2 Metabolic targets in renal cell cancer [More Info]
Brian Shuch, Yale University, New Haven, CT, USA
09:10 - 09:30O9.3 Targeting Mitochondrial Protein Complex 1 [More Info]
Anthony Tolcher, South Texas Accelerated Research Therapeutics, San Antonio, TX, USA
09:30 - 09:50O9.4 Liver-X-Receptor Inverse Agonists as Anti-Cancer Therapies that Targets the Warburg Effect and Lipogenesis [More Info]
Colin Flaveny, Saint Louis University, Saint Louis, MO, USA
09:50 - 10:10General discussion

10:10 - 10:35Break

10:35 - 12:20Plenary Session 10: Miscellaneous drugs, targets and methods [More Info]
Chair: Ruth Plummer, Newcastle University, Newcastle upon Tyne, United Kingdom
Chair: Geoffrey Shapiro, Dana-Farber Cancer Institute, Boston, MA, USA
10:35 - 10:55O10.1 Targeting the Epigenome [More Info]
Susan Bates, Columbia University, New York, NY, USA
10:55 - 11:15O10.2 Epigenetic priming for immunotherapy: what progress has there been in the promise? [More Info]
Nilofer Azad, Johns Hopkins University, Baltimore, MD, USA
11:15 - 11:35O10.3 CDK8/19: a new transcriptional target for cancer therapy [More Info]
Igor Roninson, University of South Carolina, Columbia, SC, USA
11:35 - 11:45O10.4 Lurbinectedin inhibits active transcription affecting tumor cell burden and its inflammatory microenvironment [More Info]
Carlos Galmarini, PharmaMar, Madrid, Spain
Jean-Marc Egly, IGBMC, CNRS, INSERM, University of Strasbourg, Strasbourg, France
11:45 - 11:55O10.5 Entering the era of clinical proteomics: Utilizing multiplexed targeted proteomics to guide patient care [More Info]
Todd Hembrough, Nantomics, Rockville, MD, USA
11:55 - 12:05O10.6 Initial perspectives from WINTHER, an international precision medicine trial using both DNA and RNA data to guide treatment [More Info]
Vladimir Lazar, Worldwide Innovative Networking (WIN) Consortium, Villejuif, France
12:05 - 12:20General discussion

12:20 - 13:00Lunch

13:00 - 14:15Plenary Session 11: DNA-targeted therapies [More Info]
Chair: Yves Pommier, National Cancer Institute, Bethesda, MD, USA
Chair: Patricia LoRusso, Yale Cancer Center, New Haven, CT, USA
13:00 - 13:20O11.1 Tumor DNA Targeting: It is time to wake up [More Info]
Yves Pommier, National Cancer Institute, Bethesda, MD, USA
13:20 - 13:40O11.2 DNA- and Tumor-Targeted Targeted Precision Medicine [More Info]
Anish Thomas, National Cancer Institute, Bethesda, MD, USA
13:40 - 14:00O11.3 Novel synthetic lethal approaches: beyond BRCA and DNA repair [More Info]
Christopher Lord, Institute of Cancer Research, London, UK
14:00 - 14:15General discussion

14:20 - 15:35Plenary Session 12: New targets in the androgen receptor pathway [More Info]
Chair: Christophe Massard, Institut Gustave Roussy, Villejuif, France
Chair: Sophie Postel-Vinay, Institut Gustave Roussy, Villejuif, France
14:20 - 14:40O12.1 Precision medicine in prostate cancer: Androgen Receptors pathway, biology and therapeutics [More Info]
Bertrand Tombal, Cliniques universitaires Saint Luc, Brussels, Belgium
14:40 - 15:00O12.2 DNA repair and prostate cancer: from genetics to targeted therapies [More Info]
David Olmos, Spanish National Cancer Research Centre & Institute of Biomedical Research in Malaga, Madrid, Spain
15:00 - 15:20O12.3 Immunotherapy of Prostate Cancer [More Info]
Lawrence Fong, University of California, San Francisco, CA, USA
15:20 - 15:35General discussion

15:35 - 15:40Closing remarks [More Info]
Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France